Evidence of benefit of Promitor (Tate & Lyle) for Nutritional Health
Two new research studies provide evidence that certain higher-fibre diets can in fact be well-tolerated, and that fibre may play an important role in supporting a healthy gut as well as promoting calcium absorption. In a crossover study, 23 adolescents 12-15 years old were given controlled diets over two, three-week sessions separated by a one-week washout period. The diets were identical with the exception that the test diet included daily consumption of a product that had 12 grams of Promitor (soluble corn fibre), from Tate & Lyle. Researchers found that consuming the test diet with soluble corn fibre helped increase several strains of beneficial bacteria in the gut. In addition, researchers found that consumption of the fibre changed the gut environment which appeared to have enabled greater calcium absorption.
In a second randomized controlled crossover study of 20 healthy adults, subjects were given Promitor administered as a single bolus dose and in multiple doses spread throughout the day. Up to a 40g single dose of soluble corn fibre and a 65g daily total were well-tolerated among subjects�amounts exceeding the daily recommendations for fibre, and far exceeding average actual daily intake. Results were presented at the 14th International Symposium on Microbial Ecology. "This study in adolescents shows an increase in specific beneficial bacteria � namely, bifidiobacteria, parabacterioidetes, and alistipes," said Cindy H. Nakatsu, Professor of Agronomy at Purdue University. "This is important because these data begin to provide evidence for the mechanism by which soluble corn fibre helps increase the observed calcium absorption and, adolescents everywhere could benefit from more fibre and calcium in their diets."
Related news and insights
Genentech/Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Oncopeptides announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase III OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the FDA. Pepaxto was granted accelerated approval on February 26th 2021.
Johnson & Johnson announced the FDA has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine.